ABSTRACT
BACKGROUND The SARS-CoV-2 outbreak poses challenge to healthcare systems due to high complication rates in patients with cardiometabolic diseases. Here, we identify risk factors and propose a clinical score to predict COVID-19 lethality, including specific factors for diabetes and obesity and its role in improving risk prediction.
METHODS We obtained data of confirmed and negative COVID-19 cases and their demographic and health characteristics from the General Directorate of Epidemiology of Mexican Ministry of Health. We investigated specific risk factors associated to COVID-19 positivity and mortality and explored the impact of diabetes and obesity on modifying COVID- 19 related lethality. Finally, we built a clinical score to predict COVID-19 lethality.
RESULTS Among 71,103 subjects at April 27th, 2020, we observed 15,529 subjects with SARS-CoV-2 and 1,434 deaths. Risk factors for lethality in COVID-19 includes early-onset diabetes obesity, COPD, advanced age, immunosuppression, and CKD; we observed that obesity mediates 45.5% of the effect of diabetes on COVID-19 lethality. Early-onset diabetes conferred an increased risk of hospitalization and obesity conferred an increased risk for ICU admission and intubation. Our predictive score for COVID-19 lethality included age ≥65 years, diabetes, early-onset diabetes, obesity, age <40 years, CKD, hypertension, pregnancy and immunosuppression and significantly discriminates lethal from non-lethal COVID-19 cases (c- statistic=0.830).
RESULTS Here, we propose a mechanistic approach to evaluate risk for complications and lethality attributable to COVID-19 considering the effect of obesity and diabetes in Mexico. Our score offers a clinical tool for quick determination of high-risk susceptibility patients in a first contact scenario.
- COVID-19
- SARS-CoV-2
- Diabetes
- Obesity
- Lethality
- Mexico
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
No funding received.
Author Declarations
All relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.
Yes
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
CONFLICT OF INTERESTS: Nothing to disclose.
FUNDING: This research received no specific funding
Data Availability
All data sources and R code are available for reproducibility of results at https://github.com/oyaxbell/covid_diabetesmx.